S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
My wife was skeptical... until I showed her my account balance. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
AI Stock Caught Trading Under Secret Name (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
AI Stock Caught Trading Under Secret Name (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
My wife was skeptical... until I showed her my account balance. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
AI Stock Caught Trading Under Secret Name (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
AI Stock Caught Trading Under Secret Name (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
My wife was skeptical... until I showed her my account balance. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
AI Stock Caught Trading Under Secret Name (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
AI Stock Caught Trading Under Secret Name (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
My wife was skeptical... until I showed her my account balance. (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
AI Stock Caught Trading Under Secret Name (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
AI Stock Caught Trading Under Secret Name (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

$15.94
+0.17 (+1.08%)
(As of 02/22/2024 ET)
Today's Range
$14.86
$16.93
50-Day Range
$7.18
$15.94
52-Week Range
$3.21
$16.93
Volume
34.63 million shs
Average Volume
10.41 million shs
Market Capitalization
$4.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.67

Iovance Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
42.2% Upside
$22.67 Price Target
Short Interest
Bearish
21.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.61mentions of Iovance Biotherapeutics in the last 14 days
Based on 60 Articles This Week
Insider Trading
Acquiring Shares
$2.29 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.88) to ($1.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.87 out of 5 stars

Medical Sector

27th out of 934 stocks

Biological Products, Except Diagnostic Industry

7th out of 160 stocks


IOVA stock logo

About Iovance Biotherapeutics Stock (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Stock Price History

IOVA Stock News Headlines

U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
Why Is Iovance Therapeutics (IOVA) Stock Up 35% Today?
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
2/22/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
503
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$22.67
High Stock Price Target
$34.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+42.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-395,890,000.00
Pretax Margin
-61,484.72%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.66 per share

Miscellaneous

Free Float
229,303,000
Market Cap
$4.08 billion
Optionable
Optionable
Beta
0.39

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 50)
    J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary
    Comp: $1.39M
  • Mr. Jean-Marc Bellemin M.B.A. (Age 51)
    CFO, Principal Accounting Officer & Treasurer
    Comp: $932.2k
  • Dr. Igor P. Bilinsky (Age 51)
    Chief Operating Officer
    Comp: $932.2k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 57)
    Chief Medical Officer
    Comp: $1.06M
  • Ms. Sara Pellegrino
    Vice President of Investor Relations & Public Relations
  • Ms. Tracy Winton
    Senior Vice President of Human Resources
  • Mr. Howard B. Johnson M.B.A. (Age 64)
    Chief Business Officer
  • Mr. James Ziegler M.B.A.
    Executive Vice President of Commercial
  • Dr. Raj K. Puri M.D.
    Ph.D., Executive VP of Regulatory Strategy & Translational Medicine
  • Mr. Brian Shew M.B.A.
    Senior VP & Head of Digital and Information Technology














IOVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price target for 2024?

11 equities research analysts have issued 1-year price targets for Iovance Biotherapeutics' stock. Their IOVA share price targets range from $15.00 to $34.00. On average, they predict the company's stock price to reach $22.67 in the next year. This suggests a possible upside of 42.2% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2024?

Iovance Biotherapeutics' stock was trading at $8.13 at the beginning of the year. Since then, IOVA stock has increased by 96.1% and is now trading at $15.94.
View the best growth stocks for 2024 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.46) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.46). The biotechnology company had revenue of $0.47 million for the quarter, compared to the consensus estimate of $4.50 million. During the same period in the previous year, the company earned ($0.63) EPS.

What ETFs hold Iovance Biotherapeutics' stock?
What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.91%), Artisan Partners Limited Partnership (1.89%), Balyasny Asset Management L.P. (1.53%), Goldman Sachs Group Inc. (1.44%), Dimensional Fund Advisors LP (1.37%) and Price T Rowe Associates Inc. MD (1.28%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IOVA) was last updated on 2/23/2024 by MarketBeat.com Staff